References
- Blumberg H., Dayton H. B. Naloxone and related compounds. Agonist and Antagonist Actions of Narcotic Analgesic Drugs, H. W. Kosterlitz, H. O. J. Collier, J. E. Villarreal. University Park Press, Baltimore 1973; 110–119
- Blumberg H., Dayton H. B., George M., Rapaport D. N. N-Allylnoroxymorphone: A potent narcotic antagonist. Fed. Proc 1961; 20: 311
- Blumberg H., Dayton H. B., Wolf P. S. Narcotic antagonist activity of naloxone. Fed. Proc 1965; 24: 676
- Chappel J. N., Jaffe J. H., Senay E. C. Cyclazocine in a multimodality treatment program, Comparative results. Int. J. Addict 1971; 6: 509–523
- Fink M., Freedman A. M., Resnick R., Zaks A. Clinical status of the narcotic antagonistsopiate dependence. Agonist and Antagonist Actions of Narcotic Analgesic Drugs, H. W. Kosterlitz, H. O. J. Collier, J. E. Villarreal. University Park Press, Baltimore 1973; 266–276
- Fink M., Zaks A., Sharoff R., Mora A., Bruner A., Levit S., Freedman A. M. Naloxone in heroin dependence. Clin. Pharmacol. Ther 1968; 9: 568–577
- Foldes F. F., Lunn J. N., Moore J., Brown I. M. N-Allylnoroxymorphone: A new potent narcotic antagonist. Am. J. Med. Sci 1963; 245: 23–30
- Freedman A. M., Fink M., Sharoff R., Zaks A. Cyclazocine and methadone in narcotic addiction. J. Am. Med. Assoc 1967; 202: 91–194
- Freedman A. M., Fink M., Sharoff R., Zaks A. Clinical studies of cyclazocine in the treatment of narcotic addiction. Am. J. Psychiatry 1968; 124: 1499–1504
- Jaffe J. H., Brill L. Cyclazocine, a long acting narcotic antagonist: Its voluntary acceptance as a treatment modality by narcotic abusers. Int. J. Addict 1966; 1: 99–123
- Jasinski D. R., Martin W. R., Haertzen C. A. The human pharmacology and abuse potential ofN-allylnoroxymorphone (naloxone). J. Pharmacol. Exp. Ther 1967; 157: 420–426
- Kurland A. A., Hanlon T. E., McCabe O. L. Naloxone and the narcotic abuser: A controlled study of partial blockade. Int. J. Addict 1974; 9: 663–672
- Kurland A. A., Krantz J. C., Jr., Henderson J. M., Kerman F. Naloxone and the narcotic abuser: A low dose maintenance program. Int. J. Addict 1973; 8: 127–141
- Lunn J. N., Foldes F. F., Moore J., Brown I. M. The influence of N-allyloxymorphone on the respiratory effects of oxymorphone in anaesthetized man. Pharmacologist 1961; 3: 66
- Martin W. R., Fraser H. F., Gorodetzky C. W., Rosenberg D. E. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2′-hydroxy-5, 9-dimethyl-6, 7-benzomorphan (Cyclazocine, Win-20, 740, ARC 11-C-3). J. Pharmacol. Exp. Therap 1965; 150: 426a
- Martin W. R., Gorodetzky C. W. Cyclazocine, an adjunct in the treatment of narcotic addiction. Int. J. Addict 1967; 2: 85–93
- Martin W. R., Gorodetzky C. W., McClane T. K. A Proposed Method for Ambulatory Treatment of Narcotic Addicts Using a Long-Active Orally Effective Narcotic Antagonist, Cyclazocine—An Experimental Study. paper presented at the 27th Annual Meeting of the Committee on Problems of Drug Dependence, National Academy of Sciences, National Research Council, Houston, Texas, 1965b
- McCabe O. L., Kurland A. A., Sullivan D. Paroled narcotic addicts in a verified abstinence program: Results of a five year study. Int. J. Addict 1975; 10: 211–228
- Resnick R., Fink M., Freedman A. M. Cyclazocine treatment of opiate dependence—A progress report. Compr. Psychiatry 1971; 12: 491–502
- Sadove M. S., Balagot R. C., Hatano S., Jobgen E. A. Study of narcotic antagonistN-allynoroxymorphone. J. Am. Med. Assoc 1963; 183: 666–668
- Zaks A., Jones T., Fink M., Freedman A. M. Naloxone treatment of opiate dependence. A progress report. J. Am. Med. Assoc 1971; 215: 2108–2110